Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 3:33 AM
Ignite Modification Date:
2025-12-25 @ 3:33 AM
NCT ID:
NCT03672305
Eligibility Criteria:
Inclusion Criteria:
1. Male or female patients aged 18 to 70 years (including 18 and 70 years);
2. Immune histochemistry detection was confirmed as c-met positive ; hepatocellular carcinoma, and the patient has no effective treatment at present
3. Liver tissue type: non-diffuse hepatocellular carcinoma, no extra hepatic metastasis or portal vein infiltration;
4. Cirrhosis of the liver: child-pugh A grade or child-pugh B grade, child-pugh-turcotte score \<7;
5. Routine blood test: white blood cell count (WBC) or 3 \* 10\^9/L, lymphocyte percentage (LY) 15% or higher, hemoglobin (Hb), 90g/L or higher, prothrombin time (PT), international standardization ratio (INR) 1.7 or less, or prothrombin time (PT) extend the 4 s or less, lymphocyte acuity 0.8 \* 10\^9/L;
6. The main tissues and organs of the patients are functioning well (if the organs do not meet the following standards, but the researchers believe that the diseases themselves can be included):
1. Hepatic and pancreatic functions: alanine aminotransferase/aspartate aminotransferase (ALT/AST) is 5 times of normal value, total bilirubin (TBiL) is 3.0mg/dL, albumin (ALB) is 35g/L, serum lipase is 1.5 times of normal value, and serum amylase is 1.5 times of normal value. Renal function: creatinine \<2 ULN
2. Lung function: indoor oxygen saturation greater than or equal to 95% (without oxygen inhalation)
3. Cardiac function: LVEF is greater than or equal to 40%
4. The absolute number of neutrophils is greater than or equal to 0.75 \* 10\^9/L, and platelets are greater than or equal to 50 \* 10\^9/L
7. ECOG score 0-1 or Karnofsky performance status (card score) (KPS) is greater than 60, and the expected survival time is greater than or equal to 12 weeks;
8. There are adequate venipuncture or venous sampling channels and no contraindications for lymphocyte separation;
9. No anti-tumor therapy, including chemotherapy, radiotherapy and immunotherapy (such as immunosuppressive drugs), was received within 4 weeks before enrollment, and the toxicity response of previous treatment was restored to level 1 or less (except for low-level toxicity such as hair loss);
10. Female subjects of reproductive age must have negative serum or urine pregnancy test during screening, and male and female patients agree to take effective contraceptive measures during the trial;
11. There were no other serious complications;
12. Voluntarily sign informed consent.
Exclusion Criteria:
1. Women during pregnancy (positive urine/blood pregnancy test) or lactation; A male or female who has a plan to conceive within the last 1 year; Effective contraceptive (condom or birth control pill, etc.) cannot be guaranteed for 1 year after enrollment;
2. The patients had uncontrollable infection within 4 weeks before enrollment. However, prophylactic antibiotics, antiviral and antifungal infection treatment are allowed; Active hepatitis b hepatitis c; People infected with human immunodeficiency virus (HIV);
3. Suffering from severe autoimmune disease or immunodeficiency disease;
4. The patient is allergic to large molecular biological drugs such as antibodies or cytokines;
5. The patient who has mentally ill;
6. The patient has substance abuse/addiction;
7. The patient who has a history of hepatocellular carcinoma;
8. Having severe peptic ulcer or bleeding;
9. A patient who receives an organ transplant or waits for one;
10. Patients requiring anticoagulation (e.g., warfarin or heparin);
11. Patients requiring long-term antiplatelet therapy (aspirin \> 300 mg/d; Clopidogrel dose \> 75 mg/d);
12. Organ failure patient:
1. Cardiac function: grade 3 or above according to the New York heart association (NYHA) standard
2. Liver function: C level above, according to child-pugh standard
3. Chronic kidney disease (CKD) stage 4 or above; Renal insufficiency or above
4. Lung function: severe respiratory failure, involving other organs
5. Brain function: abnormal central nervous system or disturbance of consciousness;
13. Systemic use of hormones within 4 weeks before enrollment (use of prednisone 20mg/ d or less is allowed, except for inhaled hormones);
14. The patient participated in other clinical trials within 4 weeks before enrollment;
15. The patient has been treated with radiation for the past four weeks;
16. Investigators determined that the patient was unable or unwilling to comply with protocol requirements.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
70 Years
Study:
NCT03672305
Study Brief:
Protocol Section:
NCT03672305